Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지

Overexpression of EFGR as Prognostic Factor and Effect of EGF in the Progression of Hypopharyngeal Cancer

하인두암에서 예후인자로서의 표피성장인자수용체(EGFR) 과발현과 하인두암의 진행에 있어 표피성장인자(EGF)의 역할 분석

  • Lim, Young Chang (Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine) ;
  • Choi, Eun Chang (Department of Otorhinolaryngology, College of Medicine, Yonsei University) ;
  • Kim, Yoon Tae (Department of Otolaryngology, School of Medicine, Ajou University) ;
  • Kim, Jang Hee (Department of Pathology, School of Medicine, Ajou University) ;
  • Hwang, Hye Sook (Department of Otolaryngology, School of Medicine, Ajou University) ;
  • Kang, Sung Un (Department of Otolaryngology, School of Medicine, Ajou University) ;
  • Chang, Jae Won (Department of Otolaryngology, School of Medicine, Ajou University) ;
  • Shin, Yoo Seob (Department of Otolaryngology, School of Medicine, Ajou University) ;
  • Kim, Chul-Ho (Department of Otolaryngology, School of Medicine, Ajou University)
  • 임영창 (건국대학교 의과대학 이비인후-두경부외과학교실) ;
  • 최은창 (연세대학교 의과대학 이비인후과학교실) ;
  • 김윤태 (아주대학교 의과대학 이비인후과학교실) ;
  • 김장희 (아주대학교 의과대학 병리과학교실) ;
  • 황혜숙 (아주대학교 의과대학 이비인후과학교실) ;
  • 강성운 (아주대학교 의과대학 이비인후과학교실) ;
  • 장재원 (아주대학교 의과대학 이비인후과학교실) ;
  • 신유섭 (아주대학교 의과대학 이비인후과학교실) ;
  • 김철호 (아주대학교 의과대학 이비인후과학교실)
  • Received : 2013.04.06
  • Accepted : 2013.04.22
  • Published : 2013.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

연구배경 및 목적 표피성장인자수용체(EGFR)는 HER2/neu(erbB2), HER3(erbB3), HER4(erbB4)를 포함하는 receptor tyrosine ki-nase의 erbB 그룹에 속하는 수용체이다. 표피성장인자수용체의 과발현은 다양한 종류의 암, 특히 두경부편평세포암에서 예후를 악화시킨다고 알려져 있다. 이에 저자들은 하인두편평세포암에서 표피성장인자수용체의 발현 및 분포를 확인하고, 하인두암에서 표피성장인자(EGF)가 암세포의 증식과 침습에 미치는 영향에 대해 알아보고자 하였다. 대상 및 방법 57명의 하인두편평세포암 환자의 조직에서 표피성장인자수용체의 발현을 면역화학적염색을 통해 확인하고, 이에 대해 임상병리학적 요인과 생존율에 대한 분석을 시행하고, 일부 환자의 정상 및 암조직에서 Western blot을 시행하였다. 하인두편평세포암 세포주인 FaDu에서 proliferative assay, colony dispersion, wound healing assay, invasion assay를 시행하여, 하인두암의 진행에서 표피성장인자의 역할에 대하여 분석하였다. 또한 RT-PCR과 Zymography를 통하여 Matrix metalloproteinase(MMP)-2, 9의 발현을 확인하였다. 결 과 63.2%의 하인두편평세포암 조직에서 표피성장인자수용체의 발현이 확인되었다. 표피성장인자수용체의 발현은 정상조직에서 비하여 하인두암 조직에서 유의하게 증가되어 있었으며, 병리학적 병기(p=0.022)가 올라갈수록 유의하게 증가하였으나, 증례수의 제한으로 생존율에서는 통계적 유의성을 얻지는 못했다(p=0.053). in vitro의 결과로 표피성장인자를 FaDu 세포주에 처리하였을 때, FaDu 세포주의 증식이 유의하게 증가되었으며(p<0.05), Transwell invasion chamber상 침습의 증가가 확인되었다(p<0.05). RT-PCR과 zymogram 실험상 표피성장인자처리시 FaDu 세포주의 MMP-2, 9이 발현이 증가되고 활성화되는 것이 확인하였다. 결 론 본 연구에서 표피성장인자수용체의 과발현이 하인두암의 예후 인자로서의 가능성을 확인하였고, 표피성장인자가 하인두편평세포암의 증식과 침습에 관여하는 것을 확인하였다.

Keywords

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51(1):15-36. https://doi.org/10.3322/canjclin.51.1.15
  2. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30(3 SuppI7):3-14.
  3. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol. 2001;19(18 Suppl):41S-44S.
  4. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578. https://doi.org/10.1056/NEJMoa053422
  5. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193-216. https://doi.org/10.1146/annurev.bi.48.070179.001205
  6. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579-3584.
  7. Miyaguchi M, Olofsson J, Hellquist HB. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radio therapy. Clin Otolaryngol Allied Sci. 1991;16(5):466-469. https://doi.org/10.1111/j.1365-2273.1991.tb01041.x
  8. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90(11):824-832. https://doi.org/10.1093/jnci/90.11.824
  9. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor(EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res. 2006;12(24):7242-7251. https://doi.org/10.1158/1078-0432.CCR-06-0646
  10. Davies RL, Grosse VA, Kucherlapati R, Bothwell M. Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. Proc Natl Acad Sci USA. 1980:77(7):4188-4192. https://doi.org/10.1073/pnas.77.7.4188
  11. Lemmon MA, Schlessinger J. Regulation of sigrnl transduction and signal diversity by receptor oligomerization. Trends Biochem Sci. 1994;19(11):459-463. https://doi.org/10.1016/0968-0004(94)90130-9
  12. Cowley G, Smith JA, Gusterson B, Hendler F, Ozanne B. The amount of EGF receptor is elevated on squamous cell carcinoma. Cancer Cells. 1984;1:5-10.
  13. Cowley GP, Smith JA, Gusterson BA. Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer. 1986;53(2):223-229. https://doi.org/10.1038/bjc.1986.39
  14. Gusterson B, Cowley G, McIlhinney J, Ozanne B, Fisher C, Reeves B. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer. 1985;36(6):689-693. https://doi.org/10.1002/ijc.2910360612
  15. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oneal 2001;19:3234-3243. https://doi.org/10.1200/JCO.2001.19.13.3234
  16. Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor(EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006;1:11. https://doi.org/10.1186/1748-717X-1-11
  17. Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer.1999;79(11-12):1864-1869. https://doi.org/10.1038/sj.bjc.6690297
  18. Putti TC, To KF, Hsu HC, Chan AT, Lai GM, Tse G, et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology. 2002;41(2):144-151. https://doi.org/10.1046/j.1365-2559.2002.01436.x
  19. Smith BD, Smith GL, Carter D, DiGiovanna MP, Kasmvitz KM, Sasaki CT, et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127(7):780-785.
  20. Kusukawa J, Harada H, Shima I, Sasaguri Y, Kameyama T, Morimatsu M. The significance of epidermal growth factor receptor and matrix metalloproteinase-3 in squamous cell carcinoma of the oral cavity. Eur J Cancer B Oral Oncol. 1996;32B(4):217-221.
  21. Kajanne R, Miettinen P, Mehlem A, Leivonen SK, Birrer M, Foschi M, et al. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol. 2007;212:489-497. https://doi.org/10.1002/jcp.21041